MET Tyrosine Kinase Inhibitor SGX523

Preferred Label : MET Tyrosine Kinase Inhibitor SGX523;

NCIt related terms : SGX-523;

NCIt definition : An orally bioavailable small molecule, c-Met inhibitor with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.;

UNII : WH8SQN09KJ;

CAS number : 1022150-57-7;

Molecule name : SGX523;

Détails

Origin ID

C74062;

UMLS CUI

C2346913;

Automatic exact mappings (from CISMeF team)
- SGX 523 [MeSH concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- SGX 523 [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Hepatocyte Growth Factor Receptor [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients